UroAlert - GU Oncology Weekly

February 05, 2026

Videos

Peer-to-Peer Clinical Conversations

Power and Replication Rates in Randomized Cancer Trials - Pavlos Msaouel

Pavlos Msaouel

Pavlos Msaouel discusses reproducibility of phase III randomized trials in oncology with Ashish Kamat.

Cost-Effectiveness of Bladder Cancer Treatments Varies by Patient Scenario and Preference - Amanda Myers

Amanda Myers

Amanda Myers discusses a cost-effectiveness analysis of treatments for BCG-unresponsive carcinoma in situ.

Beyond the Abstracts

Mapping Heterogeneity in the Tumor Microenvironment of Renal Cell Carcinoma Through Single-Cell Omics - Beyond the Abstract

Attendings versus Supervised Residents: Educational Results and Future Perspective in Transurethral Resection of Bladder Tumors - Beyond the Abstract

Conference Coverage

SUO 2025: Huggins Medal Lecture: What I Did and What I Am Doing

SUO 2025: PSMAddition: Top Line Results from a Phase 3 Trial of ADT and ARPI +/- 177Lu-PSMA-617 in Patients with PSMA-Positive mHSPC

ESMO 2025: Discussant – Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression

ESMO 2025: Soluble MAdCAM-1 Predicts Outcomes in Patients with Metastatic Renal Cell Carcinoma: Results from Three Independent Clinical Trials

BCANTT 2025: Tracking and Tackling an Increasing Trend in Young-Onset Bladder/Urothelial Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Disparities and temporal trends in referral for bladder cancer diagnosis: A worsening epidemic.

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).

Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.

Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.

Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.

How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database.

Impact of Hypoalbuminemia on Morbidity and Mortality After Radical Cystectomy.

Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer.

Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.

Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.

Diagnostic Performance and Clinical Utility of the Uromonitor® Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-Analysis.

Field-effect-informed urine liquid biopsy for bladder cancer.

Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network.

Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study.

Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.

Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward - Beyond the Abstract

Prognostic Factors of Trimodal Therapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

A Systematic Review of Gene-Mediated Therapy in BCG-Unresponsive NMIBC: Emerging Evidence and Future Perspectives - Beyond the Abstract

Penile & Urethral Cancers

Pathway from lichen sclerosus to squamous cell carcinoma of the penis: the oncologist's perspective.

Field effects in penile squamous cell carcinoma: Insights from Wnt-related protein expression.

Geospatial and Cell Density Analysis Using Multiplex Immunofluorescence Reveals an Important Role of Clustering Patterns of Immunosuppressive Macrophages in Survival Outcomes of Penile Squamous Cell Carcinoma.

Renal Cancer

Diagnostic practice and awareness of SDH- and FH-deficient renal cell carcinoma: results from an Italian Study Group of uropathology (GIUP) survey.

Review: Differentiating Various Renal Cell Tumors with Clear Cytoplasmic Features, Old and New, Based on Their Different Renal Tubular Origins.

Clinical Outcomes of Targeted Therapies Following HIF-2α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World Analysis.

A nomogram including body composition parameters for predicting recurrence of pT1 clear cell renal cell carcinoma: a multicenter retrospective study.

Risk Factors for RNA Integrity in Fresh-Frozen Renal Cancer Samples from Routine Practice (UroCCR 9).

Health-related Quality of Life in Localized and Metastatic Renal Cell Carcinoma: Insights from Patient-reported Outcome Measures.

Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma.

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.

Sex differences in the association of emotional approach coping with stress and quality of life among patients with renal cell carcinoma.

Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.

Percutaneous Microwave Ablation Preserves Renal Function with Similar Long Term Oncologic Outcomes Compared to Surgery for Clinical T1 Renal Cell Carcinoma.

Prostate Cancer

Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men.

Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.

Intercellular Horizontal Transfer of TXNDC5 mRNA via Extracellular Vesicles Contributes to Tumor-Associated Macrophage-Mediated Prostate Cancer Metastasis.

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.

Impact of surgical waiting list on oncological outcomes of radical prostatectomy in patients with intermediate- and high-risk prostate cancer.

Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.

Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer.

Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare data.

Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94).

Persistent bothersome urinary frequency following stereotactic body radiation therapy for clinically localized prostate cancer: rationale for prophylactic β3-agonist in men with elevated baseline international prostate symptom scores.

Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.

Improving outcomes of patients with advanced prostate cancer through a better understanding of clinical factors contributing to financial toxicity: a qualitative study.

Predictors of Successful First-Attempt Prostate Cancer Computed Tomography Simulation: A Prospective Cohort Study.

Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer.

PANDA-PLUS: Improved dataset of prostate whole slide images from PANDA Challenge with pixel-level expert annotations.

Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine.

Development of a Prognostic Prediction Model for Clinically Significant Prostate Cancer Based on Lesion Zone and Apparent Diffusion Coefficient Value Quantification.

Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer.

Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study.

PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [225Ac]Ac-PSMA Radiopharmaceutical Therapy.

68Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study.

The Geographic Mismatch Between Urologic Services and Urologists in the United States

Semi-supervised learning in prostate MRI tumor detection approaches fully supervised performance on external validation.

Molecular and Genetic Biomarkers in Prostate Cancer Active Surveillance: Recent Developments and Future Perspectives.

Transition from Transrectal Systematic to Transperineal Lesion-Focused Prostate Biopsy: A Real-World Comparative Analysis.

Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer.

Comparison of Artificial Intelligence and Radiologists in MRI-Based Prostate Cancer Diagnosis: A Meta-Analysis of Accuracy and Effectiveness.

Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?

Personalizing Prostate Cancer Education for Patients Using an EHR-Integrated LLM Agent - Beyond the Abstract

Radical Prostatectomy Outcomes in Patients with PI-RADS 5 Lesions and Favorable Prostate Cancer - Beyond the Abstract

Addition of Androgen-Receptor Pathway Inhibitors to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

Upper Tract Tumors

Localised Urothelial Carcinoma of the Upper Urinary Tract: Histopathology, Molecular Genetics, and Clinical Features.

Demographic and prognostic landscape of upper urinary tract urothelial carcinoma: an analysis of a national cancer database.

Impact of tumor location on oncological and perioperative outcomes after robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma.

Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns.

Testicular Cancer

Long-Term Disease-Free Survival After Sorafenib-Combined Chemotherapy for Refractory Metastatic Testicular Germ Cell Tumor: A Five-Year Follow-Up.

Somatic Tumor-Like Neoplasms Arising With Testicular Germ Cell Tumors: Distilling Evolving Understanding, Terminology, and Implications for the Practicing Surgical Pathologist.

From Testis to Retroperitoneum: The Role of Radiomics and Artificial Intelligence for Primary Tumors and Nodal Disease in Testicular Cancer: A Systematic Review.

Comprehensive Analysis of microRNA Expression Provides Mechanistic Insights into Transcriptomic Alteration in Primary and Metastatic Testicular Germ Cell Tumors - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC